SAB Biotherapeutics (SABS) Total Non-Current Liabilities (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Total Non-Current Liabilities data on file, last reported at $15.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 1.66% year-over-year to $15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (down 1.66% YoY) and the FY2025 annual result came in at $15.7 million, up 32.47% from the prior year.
• Total Non-Current Liabilities fell to $15.1 million in Q1 2026, from $15.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $24.4 million in Q1 2022 to a low of $11.7 million in Q2 2024.
• A 5-year average of $16.1 million and a median of $15.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 466.41% — and 2023, when it slumped 41.17%.
• Tracing SABS's Total Non-Current Liabilities over 5 years: stood at $19.5 million in 2022, then slipped by 23.86% to $14.9 million in 2023, then retreated by 20.39% to $11.8 million in 2024, then soared by 32.47% to $15.7 million in 2025, then declined by 3.67% to $15.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $15.1 million (Q1 2026), $15.7 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.